Sign in

    Ravindra Mehrotra

    Research Analyst at Evercore ISI

    Ravindra Mehrotra is an Equity Research Analyst at Evercore ISI, specializing in biotechnology sector analysis with a focus on firms such as Cyclerion Therapeutics. His track record includes direct engagement on earnings calls and in-depth coverage of biotech companies, contributing actionable insights to investors and management teams. Mehrotra began his financial markets career after advanced training in biochemistry and molecular biology and has held analytical roles in major life sciences investment research. He holds strong scientific credentials and is recognized for his expertise at the intersection of finance and biotech innovation.

    Ravindra Mehrotra's questions to Cyclerion Therapeutics (CYCN) leadership

    Ravindra Mehrotra's questions to Cyclerion Therapeutics (CYCN) leadership • Q1 2019

    Question

    Ravindra Mehrotra asked for more detail on the company's team, culture, and the collective experience that has enabled it to execute so quickly since its launch.

    Answer

    CEO Peter Hecht described the team as a blend of experienced personnel from their previous work at Ironwood and new talent from other leading companies, such as Dr. Andy Busch, who previously led R&D at Shire and played a key role in sGC stimulator development at Bayer. Hecht emphasized that the new company's culture is built on urgency, focus, and operational excellence, which is particularly effective in the orphan disease space where they can work constructively with regulatory agencies to potentially accelerate development timelines.

    Ask Fintool Equity Research AI